Curve Biosciences Appoints Dr. Amit Singal as Chief Medical Officer
Curve Biosciences, the Whole-Body Intelligence™ company, today announced the appointment of Amit Singal, M.D., as Chief Medical Officer. A nationally recognized leader in clinical management of liver diseases like cirrhosis, hepatocellular carcinoma, and MASH, Dr. Singal brings deep clinical expertise, translational research leadership, and decades of experience advancing improved outcomes for patients with liver cirrhosis such as the earlier detection of liver cancer.
Curve Biosciences Raises $40 Million to Bring Whole-Body Intelligence to Chronic Disease Monitoring
Curve Biosciences, the Whole-Body Intelligence™ company, today announced it has raised $40 million in funding led by Luma Group with participation from First Spark Ventures, Techas Capital, Micah Spear, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC, and others.
Curve Biosciences Appoints Industry Veterans to Leadership Team, Announces Commercial Advisory Board
Curve Biosciences (“Curve”), an early-stage company bringing precision to chronic disease care, today announced the addition of Nathan Hunkapiller, PhD, as chief scientific officer (CSO) and Chuba Oyolu, PhD, as chief technology officer (CTO). Hunkapiller leads Curve’s research and development, and Oyolu oversees technology development and software.
